首页> 外文期刊>JAMA: the Journal of the American Medical Association >Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.
【24h】

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.

机译:他汀类药物对冠心病风险的影响:一项随机对照试验的荟萃分析。

获取原文
获取原文并翻译 | 示例
       

摘要

CONTEXT: Lowering low-density lipoprotein cholesterol (LDL-C) is known to reduce risk of recurrent coronary heart disease in middle-aged men. However, this effect has been uncertain in elderly people and women. OBJECTIVE: To estimate the risk reduction of coronary heart disease and total mortality associated with statin drug treatment, particularly in elderly individuals and women. DATA SOURCES: Trials published in English-language journals were retrieved by searching MEDLINE (1966-December 1998), bibliographies, and authors' reference files. STUDY SELECTION: Studies in which participants were randomized to statin or control treatment for at least 4 years and clinical disease or death was the primary outcome were included in the meta-analysis (5 of 182 initially identified). DATA EXTRACTION: Information on sample size, study drug duration, type and dosage of statin drug, participant characteristics at baseline, reduction in lipids during intervention, and outcomes was abstracted independently by 2 authors (J.H. and S.V.) using a standardized protocol. Disagreements were resolved by consensus. DATA SYNTHESIS: Data from the 5 trials, with 30 817 participants, were included in this meta-analysis. The mean duration of treatment was 5.4 years. Stati n drug treatment was associated with a20% reduction in total cholesterol, 28% reduction in LDL-C, 13% reduction in triglycerides, and 5% increase in high-density lipoprotein cholesterol. Overall, statin drug treatment reduced risk 31 % in major coronary events (95% confidence interval [CI], 26%-36%) and 21 % in all-cause mortality (95% CI, 14%-28%). The risk reduction in major coronary events was similar between women (29%; 95% Cl, 13 %-42 %) and men (31 %; 95% CI, 26%-35%), and between persons aged at least 65 years (32%; 95% CI, 23%-39%) and persons younger than 65 years (31 %; 95% CI, 24%-36%). CONCLUSIONS: Our meta-analysis indicates that reduction in LDL-C associated with statin drug treatment decreases the risk of coronary heart disease and all-cause mortality. The risk reduction was similar for men and women and for elderly and middle-aged persons.
机译:背景:降低低密度脂蛋白胆固醇(LDL-C)可以降低中年男性复发性冠心病的风险。但是,这种影响在老年人和妇女中尚不确定。目的:评估与他汀类药物治疗有关的冠心病风险降低和总死亡率,尤其是在老年人和女性中。数据来源:通过检索MEDLINE(1966年-1998年12月),参考书目和作者的参考文件,检索了英语期刊上发表的试验。研究选择:荟萃分析(其中182项中有5项纳入了研究),其中参与者被随机分配接受他汀类药物或对照治疗至少4年,并且以临床疾病或死亡为主要结果。数据提取:2位作者(J.H.和S.V.)使用标准化方案独立提取了样本量,研究用药时间,他汀类药物的类型和剂量,基线时的受试者特征,干预期间血脂减少以及结果的信息。分歧通过协商解决。数据综合:这项荟萃分析包括来自5个试验的30 817名参与者的数据。平均治疗时间为5.4年。稳定的药物治疗与总胆固醇减少20%,LDL-C减少28%,甘油三酸酯减少13%和高密度脂蛋白胆固醇增加5%有关。总体而言,他汀类药物治疗可将主要冠状动脉事件的风险降低31%(95%置信区间[CI],26%-36%),全因死亡率降低21%(95%CI,14%-28%)。女性(29%; 95%Cl,13%-42%)和男性(31%; 95%CI,26%-35%)之间以及年龄至少65岁的人群中,重大冠状动脉事件的风险降低相似。 (32%; 95%CI,23%-39%)和65岁以下的人(31%; 95%CI,24%-36%)。结论:我们的荟萃分析表明,与他汀类药物治疗相关的LDL-C降低可降低冠心病和全因死亡率的风险。男女和老年人和中年人的风险降低程度相似。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号